Hyderabad: Dr Reddy’s Laboratories Ltd said that it has started selling desloratadine ODT, a bioequivalent generic version of Merck and Co. Inc.’s Clarinex and Reditabs brands in the US market. Desloratadine ODT is used in treatment of allergies.

Dr Reddy’s abbreviated new drug application (ANDA) for desloratadine ODT is approved by the US Food and Drug Administration (USFDA).

The Clarinex and Reditabs brand had US sales of around $5.3 million for the most recent 12 months ending November, according to US-based healthcare information provider IMS Health.

Dr Reddy’s desloratadine ODT will be available in 2.5mg and 5mg dosages.

Shares of Dr. Reddy’s rose 1.7% to 1,962 on BSE at 11am. The benchmark Sensex gained by 0.23% to 19,970.19 points.